Menu
RWE Study
Discover the promise of our DTx application as we undergo clinical trials.
In India, where more than 30 million people suffer from chronic obstructive pulmonary disease (COPD) and asthma, there is a pressing need to explore innovative technologies that can effectively manage these chronic conditions and enhance patients’ quality of life.
Addressing this need, We have developed a revolutionary digital therapeutics (DTx) platform called MyTatva. To evaluate its potential, we are set to initiate clinical trials across multiple centers in India. This study is known as BREATHE DTx (Board of Respiratory Experts for Advanced Therapeutic Health Ecosystem – DTx). In this study, a randomized sample of 150-200 subjects will participate, aiming to assess the efficacy and benefits experienced by users.
Based on the trial results, we plan to introduce this groundbreaking digital therapeutics solution for managing COPD and Asthma in India. Leading the study is Dr. Agam Vora, a renowned pulmonologist from Mumbai, who will oversee a panel of distinguished pulmonologists from various parts of India. This will be conducted at eight centers across the country.
Spanning a duration of six months, the Randomized Controlled Trial (RCT) will comprehensively evaluate the effectiveness of MyTatva through real-world evidence gathered during the study.
